Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Clinical trial NCT00512798 · TERMINATED

Trial details

NCT number: NCT00512798
Sponsor: Vanderbilt-Ingram Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Brain and Central Nervous System Tumors Melanoma Solid Tumor

Start date: 2003-06-01
Primary completion: 2006-07-01
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.